Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis.
The efficacy of therapeutic aerosolized amphotericin B (AMB) was studied in a steroid-immunosuppressed murine model of invasive pulmonary aspergillosis. Nebulized liposomal AMB can be a valid approach to the treatment of this infection, with subjects showing significantly improved survival relative to that of subjects given intravenous deoxycholate AMB, as well as lower lung weights and pulmonary glucosamine levels.
Infectious Diseases Research Laboratory, Infectious Diseases Division, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. jgavalda@vhebron.net
Joan
J
Gavaldà
María-Teresa
MT
Martín
Pedro
P
López
Xavier
X
Gomis
José-Luís
JL
Ramírez
Dolors
D
Rodríguez
Oscar
O
Len
Yolanda
Y
Puigfel
Isabel
I
Ruíz
Albert
A
Pahissa
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy / Q000382:microbiology; D001232:Aspergillus fumigatus / Q000187:drug effects*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents; D008081:Liposomes / Q000008:administration & dosage / Q000627:therapeutic use*; D008172:Lung Diseases, Fungal / Q000188:drug therapy* / Q000382:microbiology; D009330:Nebulizers and Vaporizers; D051381:Rats; D017208:Rats, Wistar; D013256:Steroids; D016896:Treatment Outcome
D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D008081:Liposomes; D013256:Steroids; D000666:Amphotericin B